NO994760L - Vandige immunologiske adjuvanspreparat av monofosforyllipid A - Google Patents
Vandige immunologiske adjuvanspreparat av monofosforyllipid AInfo
- Publication number
- NO994760L NO994760L NO994760A NO994760A NO994760L NO 994760 L NO994760 L NO 994760L NO 994760 A NO994760 A NO 994760A NO 994760 A NO994760 A NO 994760A NO 994760 L NO994760 L NO 994760L
- Authority
- NO
- Norway
- Prior art keywords
- surfactant
- lipid
- derivative
- attenuated
- monophosphoryl lipid
- Prior art date
Links
- 229940035032 monophosphoryl lipid a Drugs 0.000 title abstract 3
- 239000000568 immunological adjuvant Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 6
- 230000002238 attenuated effect Effects 0.000 abstract 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83107397A | 1997-04-01 | 1997-04-01 | |
| PCT/US1998/006528 WO1998043670A2 (en) | 1997-04-01 | 1998-04-01 | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994760D0 NO994760D0 (no) | 1999-09-30 |
| NO994760L true NO994760L (no) | 1999-11-26 |
Family
ID=25258229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994760A NO994760L (no) | 1997-04-01 | 1999-09-30 | Vandige immunologiske adjuvanspreparat av monofosforyllipid A |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0971739B1 (pl) |
| JP (1) | JP5019494B2 (pl) |
| KR (1) | KR100603884B1 (pl) |
| CN (2) | CN1259052A (pl) |
| AT (1) | ATE278419T1 (pl) |
| AU (1) | AU743114B2 (pl) |
| BR (1) | BR9811262A (pl) |
| CA (1) | CA2284586C (pl) |
| DE (1) | DE69826842T2 (pl) |
| ES (1) | ES2227825T3 (pl) |
| HU (1) | HUP0001403A3 (pl) |
| IL (2) | IL132126A0 (pl) |
| NO (1) | NO994760L (pl) |
| NZ (1) | NZ338101A (pl) |
| PL (1) | PL190237B1 (pl) |
| PT (1) | PT971739E (pl) |
| TR (1) | TR199902437T2 (pl) |
| WO (1) | WO1998043670A2 (pl) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
| GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| DK2266603T3 (da) | 2000-10-18 | 2012-11-05 | Glaxosmithkline Biolog Sa | Tumorvacciner |
| US20040071734A1 (en) | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
| US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| US8048433B2 (en) * | 2004-12-17 | 2011-11-01 | Nvi Nederlands Vaccininstituut | Deacylation of LPS in gram negative bacteria |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| GB0504436D0 (en) | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| KR20130110233A (ko) | 2005-04-29 | 2013-10-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법 |
| AP2745A (en) * | 2005-08-02 | 2013-09-30 | Novartis Vaccines & Diagnostic | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US8018440B2 (en) | 2005-12-30 | 2011-09-13 | Microsoft Corporation | Unintentional touch rejection |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| HUE036180T2 (hu) | 2006-09-26 | 2018-06-28 | Infectious Disease Res Inst | Szintetikus adjuvánst tartalmazó vakcina készítmény |
| US8836648B2 (en) | 2009-05-27 | 2014-09-16 | Microsoft Corporation | Touch pull-in gesture |
| HUE031051T2 (en) | 2009-06-05 | 2017-06-28 | Infectious Disease Res Inst | Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it |
| FR2954703B1 (fr) | 2009-12-28 | 2013-12-13 | Chu Nantes | Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes |
| US9411504B2 (en) | 2010-01-28 | 2016-08-09 | Microsoft Technology Licensing, Llc | Copy and staple gestures |
| US8261213B2 (en) | 2010-01-28 | 2012-09-04 | Microsoft Corporation | Brush, carbon-copy, and fill gestures |
| US9519356B2 (en) | 2010-02-04 | 2016-12-13 | Microsoft Technology Licensing, Llc | Link gestures |
| US9367205B2 (en) | 2010-02-19 | 2016-06-14 | Microsoft Technolgoy Licensing, Llc | Radial menus with bezel gestures |
| US9310994B2 (en) | 2010-02-19 | 2016-04-12 | Microsoft Technology Licensing, Llc | Use of bezel as an input mechanism |
| US8799827B2 (en) | 2010-02-19 | 2014-08-05 | Microsoft Corporation | Page manipulations using on and off-screen gestures |
| US8707174B2 (en) | 2010-02-25 | 2014-04-22 | Microsoft Corporation | Multi-screen hold and page-flip gesture |
| US9454304B2 (en) | 2010-02-25 | 2016-09-27 | Microsoft Technology Licensing, Llc | Multi-screen dual tap gesture |
| US9075522B2 (en) | 2010-02-25 | 2015-07-07 | Microsoft Technology Licensing, Llc | Multi-screen bookmark hold gesture |
| US8751970B2 (en) | 2010-02-25 | 2014-06-10 | Microsoft Corporation | Multi-screen synchronous slide gesture |
| US8612874B2 (en) | 2010-12-23 | 2013-12-17 | Microsoft Corporation | Presenting an application change through a tile |
| US8689123B2 (en) | 2010-12-23 | 2014-04-01 | Microsoft Corporation | Application reporting in an application-selectable user interface |
| US9423951B2 (en) | 2010-12-31 | 2016-08-23 | Microsoft Technology Licensing, Llc | Content-based snap point |
| US9383917B2 (en) | 2011-03-28 | 2016-07-05 | Microsoft Technology Licensing, Llc | Predictive tiling |
| GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9658766B2 (en) | 2011-05-27 | 2017-05-23 | Microsoft Technology Licensing, Llc | Edge gesture |
| US9104440B2 (en) | 2011-05-27 | 2015-08-11 | Microsoft Technology Licensing, Llc | Multi-application environment |
| US9104307B2 (en) | 2011-05-27 | 2015-08-11 | Microsoft Technology Licensing, Llc | Multi-application environment |
| US9158445B2 (en) | 2011-05-27 | 2015-10-13 | Microsoft Technology Licensing, Llc | Managing an immersive interface in a multi-application immersive environment |
| US9557909B2 (en) | 2011-09-09 | 2017-01-31 | Microsoft Technology Licensing, Llc | Semantic zoom linguistic helpers |
| US9244802B2 (en) | 2011-09-10 | 2016-01-26 | Microsoft Technology Licensing, Llc | Resource user interface |
| US9146670B2 (en) | 2011-09-10 | 2015-09-29 | Microsoft Technology Licensing, Llc | Progressively indicating new content in an application-selectable user interface |
| US20150190501A1 (en) | 2011-09-12 | 2015-07-09 | Imperial Innovations Limited | Methods and compositions for raising an immune response to hiv |
| SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccines for hsv-2 |
| EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| WO2014043189A1 (en) | 2012-09-14 | 2014-03-20 | The Regents Of The University Of Colorado, A Body Corporate | Conditionally replication deficient herpes viruses and use thereof in vaccines |
| US9582122B2 (en) | 2012-11-12 | 2017-02-28 | Microsoft Technology Licensing, Llc | Touch-sensitive bezel techniques |
| EP2986303B1 (en) | 2013-04-18 | 2020-02-26 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| US9477337B2 (en) | 2014-03-14 | 2016-10-25 | Microsoft Technology Licensing, Llc | Conductive trace routing for display and bezel sensors |
| EA037818B1 (ru) * | 2014-03-26 | 2021-05-25 | Глаксосмитклайн Байолоджикалс С.А. | Мутантные стафилококковые антигены |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| EP3138579A1 (en) | 2015-09-05 | 2017-03-08 | Biomay Ag | Fusion protein for use in the treatment of a hepatitis b virus infection |
| GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| EP3295956A1 (en) | 2016-09-20 | 2018-03-21 | Biomay Ag | Polypeptide construct comprising fragments of allergens |
| CA3078223A1 (en) | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| WO2019175145A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against urinary tract infections |
| EP3569612A1 (en) | 2018-05-18 | 2019-11-20 | Biomay Ag | Treatment and prevention of house dust mite allergies |
| WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| EA202192392A1 (ru) | 2019-03-18 | 2022-02-09 | Янссен Фармасьютикалз, Инк. | Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения |
| IL291821A (en) | 2019-10-02 | 2022-06-01 | Janssen Vaccines & Prevention Bv | Staphylococcus peptides and methods of use |
| JP7485771B2 (ja) | 2020-01-16 | 2024-05-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | ＦｉｍＨ変異体、その組成物、及びその使用 |
| PH12023550020A1 (en) | 2020-09-17 | 2024-03-11 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| US11725028B2 (en) | 2021-01-12 | 2023-08-15 | Janssen Pharmaceuticals, Inc. | FimH mutants, compositions therewith and use thereof |
| CN117222427A (zh) | 2021-04-01 | 2023-12-12 | 杨森制药公司 | 大肠杆菌o18生物缀合物的生产 |
| US20240180940A1 (en) * | 2021-05-27 | 2024-06-06 | Revelation Biosciences, Inc. | Mpla compositions and methods of use |
| CN121221758B (zh) * | 2025-12-02 | 2026-03-03 | 华诺泰生物医药科技(成都)有限公司 | 一种即用型稳定3d-mla佐剂溶液的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5068191A (en) * | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| US5552141A (en) * | 1991-10-30 | 1996-09-03 | Ribi; Hans O. | Polymeric immunological adjuvants |
| EP0689454B2 (en) * | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
-
1998
- 1998-04-01 PL PL98336698A patent/PL190237B1/pl not_active IP Right Cessation
- 1998-04-01 EP EP98915239A patent/EP0971739B1/en not_active Expired - Lifetime
- 1998-04-01 CN CN98804685A patent/CN1259052A/zh active Pending
- 1998-04-01 WO PCT/US1998/006528 patent/WO1998043670A2/en not_active Ceased
- 1998-04-01 IL IL13212698A patent/IL132126A0/xx active IP Right Grant
- 1998-04-01 TR TR1999/02437T patent/TR199902437T2/xx unknown
- 1998-04-01 NZ NZ338101A patent/NZ338101A/en unknown
- 1998-04-01 PT PT98915239T patent/PT971739E/pt unknown
- 1998-04-01 ES ES98915239T patent/ES2227825T3/es not_active Expired - Lifetime
- 1998-04-01 CN CNB2004100713486A patent/CN1326564C/zh not_active Expired - Fee Related
- 1998-04-01 DE DE69826842T patent/DE69826842T2/de not_active Expired - Lifetime
- 1998-04-01 KR KR1019997008958A patent/KR100603884B1/ko not_active Expired - Fee Related
- 1998-04-01 AU AU69473/98A patent/AU743114B2/en not_active Ceased
- 1998-04-01 BR BR9811262-7A patent/BR9811262A/pt not_active Application Discontinuation
- 1998-04-01 JP JP54200198A patent/JP5019494B2/ja not_active Expired - Lifetime
- 1998-04-01 AT AT98915239T patent/ATE278419T1/de active
- 1998-04-01 CA CA2284586A patent/CA2284586C/en not_active Expired - Lifetime
- 1998-04-01 HU HU0001403A patent/HUP0001403A3/hu unknown
-
1999
- 1999-09-29 IL IL132126A patent/IL132126A/en not_active IP Right Cessation
- 1999-09-30 NO NO994760A patent/NO994760L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL132126A (en) | 2006-10-05 |
| EP0971739A2 (en) | 2000-01-19 |
| EP0971739B1 (en) | 2004-10-06 |
| HUP0001403A3 (en) | 2003-05-28 |
| JP5019494B2 (ja) | 2012-09-05 |
| AU743114B2 (en) | 2002-01-17 |
| DE69826842T2 (de) | 2005-11-24 |
| PL336698A1 (en) | 2000-07-03 |
| NZ338101A (en) | 2002-03-28 |
| ATE278419T1 (de) | 2004-10-15 |
| CA2284586C (en) | 2011-02-08 |
| CA2284586A1 (en) | 1998-10-08 |
| HUP0001403A2 (hu) | 2000-09-28 |
| WO1998043670A2 (en) | 1998-10-08 |
| AU6947398A (en) | 1998-10-22 |
| ES2227825T3 (es) | 2005-04-01 |
| TR199902437T2 (xx) | 2000-01-21 |
| BR9811262A (pt) | 2000-10-17 |
| KR20010005882A (ko) | 2001-01-15 |
| CN1575815A (zh) | 2005-02-09 |
| PL190237B1 (pl) | 2005-11-30 |
| NO994760D0 (no) | 1999-09-30 |
| JP2001526640A (ja) | 2001-12-18 |
| WO1998043670A3 (en) | 1998-12-30 |
| KR100603884B1 (ko) | 2006-07-24 |
| PT971739E (pt) | 2004-12-31 |
| CN1326564C (zh) | 2007-07-18 |
| DE69826842D1 (de) | 2004-11-11 |
| CN1259052A (zh) | 2000-07-05 |
| HK1026613A1 (en) | 2000-12-22 |
| IL132126A0 (en) | 2001-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO994760L (no) | Vandige immunologiske adjuvanspreparat av monofosforyllipid A | |
| DE60037514D1 (de) | Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a | |
| US6500453B2 (en) | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom | |
| CA2279935C (en) | Chelating immunostimulating complexes | |
| US5709879A (en) | Vaccine compositions containing liposomes | |
| JP2502234B2 (ja) | リポソ―ム含有ワクチン組成物 | |
| US5879703A (en) | Encapsulation of active ingredients into lipid vesicles | |
| DK15087D0 (da) | Immunogenkomplekser og deres anvendelse i laegemidler, isaer vacciner | |
| Han et al. | Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization | |
| JP2001523216A (ja) | 新規のアジュバント組成物と、それからなるワクチン製剤 | |
| MXPA97003480A (en) | Immunogeni compositions | |
| US20080226709A1 (en) | Phospholipid membrane preparation | |
| AU751051B2 (en) | Adjuvant comprising pulmonary surfactant | |
| Sachetelli et al. | Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal–tobramycin formulation for the treatment of chronic infections in lungs | |
| KR0178422B1 (ko) | 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| KR0173366B1 (ko) | B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| KR0173365B1 (ko) | C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| DE69505236T2 (de) | Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel | |
| KR100406503B1 (ko) | 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신 | |
| KR100189701B1 (ko) | B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀 | |
| HK1012991B (en) | Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |